Low data variability

Our core ECG laboratory provides a centralised system for all our studies. High precision ECG acquisition in our clinic provides meaningful ECG analysis with a smaller sample size, making us the ideal choice for the integration of cardiac safety in FIH and MAD studies.

We are a leading publisher in cardiology and have publicly accessible credentials. We are proud of our integrity, our professional growth and experience in this field.

Learn more about our ECG Lab

Exceptional ECG generation

We undertake and analyse several cardiological assessments using state-of-the-art equipment to understand and explain abnormal ECG data obtained during a clinical study of a new chemical entity.

Learn more about our Cardio Analysis Services

Experts in cardiac safety

Richmond Pharmacology’s Core ECG Laboratory team are based within St George’s Hospital Medical School, London and are made up of highly experienced cardiologists headed by Professor John Camm, a key opinion leader in TQT Trials.

Learn more about our expert cardiologists

AGAH Annual Meeting 2014 Mitigating risks in early medicines development

10
January 2014

View Articles

A volunteer panel the size of a city...

21
November 2013

View Articles

Richmond Pharmacology presents latest Thorough QT study at the ASCPT 2014 Annual Meeting

3
March 2013

Moxifloxacin is used as a probe to confirm assay sensitivity in thorough electrocardiogram (ECG) studies. A meal shortens the QT interval and in some instances it is desirable to use moxifloxacin after a meal which may affect PK or PD or both; however there is no published data.

View Articles

Joint Conference of European Human Pharmacological Societies CLUB PHASE I (France), AGAH (Germany), BAPU (Belgium), AHPPI (UK)

28
February 2013

View Articles

RPL presents further confirmation of the food effect on the QTc interval

30
November 2012

View Articles

Cardiac Safety: Key issues and best practice for Thorough QT Studies and Intensive Phase I QT Studies

7
November 2012

View Articles

Latest news

Richmond Appoints Lisa Campbell as Director of Regulatory Strategy

April 23, 2025
Richmond Pharmacology is pleased to announce the appointment of Lisa Campbell as Director of Regulatory Strategy
Read more

Von Willebrand Disease Trial – First Stage of Hemab Therapeutics’ Trial Completed and New Patients Invited to Enrol

April 2, 2025
Richmond has completed dosing the first cohort of patients in Velora Pioneer, a phase 1/2 clinical trial investigating Hemab...
Read more

Events

Swiss Biotech Day 2025

5–6 May 2025
Richmond Pharmacology is pleased to confirm our participation at Swiss Biotech Day 2025
View event